Miura Tomofumi, Suzuki Nobuaki, Ozeki Yutaka, Nakamura Junichiro, Yamada Satoshi, Miura Tsutomu, Yanagi Masahiko, Sato Kazuhiro, Takahashi Toru
Division of Gastroenterology and Hepatology, Nagaoka Red Cross Hospital.
Gan To Kagaku Ryoho. 2009 Oct;36(10):1757-60.
A 78-year-old man was admitted for obstructive jaundice and unresectable bile duct cancer on March 4, 2008. Since biliary drainage was extremely difficult, he began 2 treatment courses of gemcitabine hydrochloride (GEM 800 mg/m(2) on days 1, 8, 15 every 4 weeks). He suffered from dry cough and dyspnea on May 13, 2008. He was diagnosed as GEM-induced interstitial pneumonia with severe hypoxemia by CT scan and arterial blood gas examination. He recovered with two courses of steroid pulse therapy, diuretics and antibiotics. Alternatively, he was given oral S-1 ( 80 mg/m(2) 4 weeks on and 2 weeks off) from June 12, 2008. His QOL was well kept without jaundice for as long as a half year. This is the first report of GEM-induced interstitial pneumonia in bile duct cancer. In conclusion, interstitial pneumonia must be taken into consideration as a rare adverse reaction when GEM is used for biliary neoplasms.
